On The Horizon- FDA Grants Fast Track Designation for OGX-011 in The Treatment of Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]

Increased Survival Demonstrated in a Phase II Trial of OGX-011

Results from a randomized phase II study presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting indicates there might be a new drug on the horizon for men with advanced prostate cancer. OncoGenex Pharmaceuticals drug known as OGX-011 extended the survival of patients with advanced prostate cancer by almost seven months in [...]

Phase III Clinical Trial for OGX_011 – A Treatment for Failed Chemotherapy

At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]